TITLE

Naproxen and Esomepra zole Delayed-Release Tablets (Vimovo)

AUTHOR(S)
Elliott, William T.; Chan, James
PUB. DATE
June 2010
SOURCE
Internal Medicine Alert;6/29/2010, Vol. 32 Issue 12, p94
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers information on the Vimovoâ„¢ delayed-release tablet and nonsteroidal anti-inflammatory agent and proton pump inhibitor combination of Naproxen and Esomeprazole (NAP\ESO) from AstraZeneca PLC.
ACCESSION #
51707172

 

Related Articles

  • Nexium 24HR Makes Rx-to-O-T-C Switch.  // MMR;6/9/2014, Vol. 31 Issue 9, p16 

    The article reports on the over the counter (O-T-C) availability of the drug brand Nexium 24HR (esomeprazole magnesium) from the Pfizer Inc. in the U.S. and mentions that the company acquired the global O-T-C rights to Nexium from the pharmaceutical firm AstraZeneca in August 2012.

  • Product News. Vimovo Approved for Several Indications.  // Journal of Gerontological Nursing;Aug2010, Vol. 36 Issue 8, p51 

    The author reports that the U.S. Food and Drug Administration has approved Vimovo (naproxen and esomeprazole magnesium) delayed-release tablets for the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of the development of gastric ulcers.

  • FDA: No increased risk of adverse events with Prilosec, Nexium.  // Cardiology Today;Jan2008, Vol. 11 Issue 1, p4 

    The article focuses on a statement issued by the U.S. Food and Drug Administration (FDA) regarding the risk of heart problems associated with omeprazole and esomeprazole, both from AstraZeneca. FDA conducted an Early Communication of an Ongoing Safety Review of AstraZeneca's drugs after...

  • Prilosec and Nexium Cleared. Elliott, William T. // Clinical Oncology Alert;Feb2008 Pharmacology Watch, Vol. 24, p1 

    The article reports on a statement published by the U.S. Food and Drug Administration (FDA) on its Web site that the drugs omeprazole and esomeprazole are not associated with increased rates of cardiac events. FDA reviewed the two studies presented by AstraZeneca which raise the question of...

  • Pfizer Buys OTC Rights to Heartburn Drug Nexium.  // MondayMorning;8/20/2012, Vol. 20 Issue 33, p1 

    The article focuses on the heartburn drug Nexium for over-the-counter use by Pfizer Inc. in New York who has agreed to acquire rights to market AstraZeneca Plc's in London, England paying 250 million US dollars up front as well as milestone and royalty payments. It states that the company has...

  • Pozen, AstraZeneca Start Phase III Trials In Arthritis.  // Bioworld Week;9/17/2007, Vol. 15 Issue 38, p2 

    The article reports that Pozen Inc. has launched Phase III trials with its AstraZeneca PLC partnered arthritis compound, PN 400. The deal terms of PN 400 have been changed with the start of Phase III studies. AstraZeneca is providing Pozen up to $345m for development, with $30m initially and...

  • MINAKEM ACQUIRES API PLANT FROM ASTRAZENECA. Ramesh, Deepti // Chemical Week;6/1/2009, Vol. 171 Issue 15, p21 

    The article reports on the acquisition of multipurpose active pharma ingredients (API) plant at Dunkirk, France from AstraZeneca by Minakem, a manufacturers of pharmaceutical intermediates and API. In addition, the company has signed another contract with AstraZeneca for the supply of...

  • FDA Approves Nexium for the Treatment of Short-Term GERD in Children 1 to 11 Years Old.  // Exceptional Parent;May2008, Vol. 38 Issue 5, p10 

    The article reports on the announcement from AstraZeneca that the U.S. Food and Drug Administration (FDA) has approved the use of esomeprazole magnesium under the brand name NEXIUM in children ages 1 to 11 years old for the short-term treatment of gastroesophageal reflux disease (GERD) for up to...

  • FDA early communication flags Nexium/Prilosec. Arnold, Matthew // Medical Marketing & Media;Sep2007, Vol. 42 Issue 9, p14 

    The article reports on the release of the new media relations tool that flags AstraZeneca PLC's Nexium and Prilosec, by the Food and Drug Administration (FDA) in the U.S. The August 9, 2007 communiqué concerns on the potential cardiovascular risks associated with the use of the two drugs. FDA...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics